Tuesday, October 4, 2022


Biotechnology News Magazine

iSpecimen Names Chief Financial Officer, Tracy Curley, Interim CEO

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today the immediate appointment of Tracy Curley as interim CEO, replacing current Chief Executive Officer and President, Christopher Ianelli.

In addition to serving as interim CEO, Ms. Curley will remain CFO. The Board of Directors (the “Board”) is currently reviewing the Company’s near- and long-term needs pertaining to the role of Chief Executive Officer.

On September 19, 2022, Dr. Ianelli gave the Board a notice of departure to vacate his positions as Chief Executive Officer and President, effective October 24, 2022, as a result of the non-renewal of his Executive Employment Agreement dated June 21, 2021. Pursuant to the mutual agreement of Dr. Ianelli and the Board, Dr. Ianelli vacated his positions as Chief Executive Officer and President on September 21, 2022.

On September 20, 2022, Jill Mullan gave the Board a notice of departure to vacate her position as Chief Operating Officer, effective October 24, 2022, as a result of the non-renewal of her Executive Employment Agreement dated June 21, 2021.

In order to assure a smooth transition, Dr. Ianelli and Ms. Mullan have both offered and agreed to continue to provide services as employees of iSpecimen through the termination of their employment with the Company on October 24, 2022. The Company is currently negotiating Separation Agreements with each of Dr. Ianelli and Ms. Mullan, which are expected to include the financial and other terms of each of their terminations as executive officers of the Company.

“First, allow me to extend our appreciation to Chris and Jill for their vision, guidance, and support. At the same time, I want to thank the current leadership team and everyone at iSpecimen for their dedication to achieving excellence. I also wish to convey the confidence the Board and I have in the team’s ability to successfully operate the business without missing a beat,” said Ms. Curley, Chief Financial Officer and interim-CEO. “We currently have several business initiatives underway that, over time, will further strengthen our leadership position and be transformational in the biospecimen procurement industry. Our business and balance sheet are strong, which is especially important during the current macroeconomic environment. Let us not forget the vital role iSpecimen serves in advancing breakthrough science and saving lives.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine